XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Xyrem$447,809 $425,644 $1,302,492 $1,207,173 
Defitelio/defibrotide 50,241 37,604 140,387 125,159 
Erwinaze/Erwinase20,145 34,024 90,560 122,545 
Vyxeos30,825 29,581 90,113 89,886 
Zepzelca36,941 — 36,941 — 
Sunosi9,116 987 19,618 987 
Other1,872 4,481 5,246 13,325 
Product sales, net596,949 532,321 1,685,357 1,559,075 
Royalties and contract revenues3,939 5,381 12,693 20,946 
Total revenues$600,888 $537,702 $1,698,050 $1,580,021 
The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
United States$548,410 $492,366 $1,542,990 $1,436,160 
Europe45,778 35,037 125,229 106,956 
All other6,700 10,299 29,831 36,905 
Total revenues$600,888 $537,702 $1,698,050 $1,580,021 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
ESSDS74 %79 %77 %76 %
McKesson10 %12 %11 %14 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45 days.
Contract Liabilities - Deferred Revenue
The deferred revenue balance as of September 30, 2020 primarily related to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements granting Nippon Shinyaku exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $1.2 million and $3.5 million during the three and nine months ended September 30, 2020, respectively, relating to these upfront payments. The deferred revenue balances are being recognized over an average of four
years representing the period over which we expect to perform our research and developments obligations under each agreement.
The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the nine months ended September 30, 2020 (in thousands): 
Contract Liabilities
Balance as of December 31, 2019$9,581 
Amount recognized within royalties and contract revenues(3,540)
Balance as of September 30, 2020$6,041